Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review

被引：7
|
作者：
Elsbernd, Paul M. [1 ]
Carter, Jonathan L. [1 ]
机构：
[1] Mayo Clin, Dept Neurol, 13400 East Shea Blvd, Scottsdale, AZ 85259 USA
来源：
BIOLOGICS-TARGETS & THERAPY | 2021年 / 15卷
关键词：
monoclonal antibodies; multiple sclerosis; relapsing; progressive; review; NATALIZUMAB ANTIBODIES; INTERFERON BETA-1A; CONTROLLED TRIAL; RISK; ALEMTUZUMAB; RITUXIMAB; OCRELIZUMAB; PLACEBO; MECHANISMS; SAFETY;
D O I：
10.2147/BTT.S267273
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Monoclonal antibody therapies have secured an important role in the therapeutic landscape for the treatment of both relapsing and progressive forms of multiple sclerosis due to their potent efficacy, convenient dosing schedules, and well-defined side effect profiles. Each therapy has unique risks and benefits associated with its specific mechanism of action which ultimately guides clinical decision-making for individual patients. This review will summarize the mechanisms of action, evidence leading to their approval, and clinically relevant considerations for each of the current monoclonal antibody therapies approved for the treatment of multiple sclerosis.
引用
收藏
页码：255 / 263
页数：9
相关论文
共 50 条
  • [21] Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair
    Joachim Havla
    Reinhard Hohlfeld
    Neurotherapeutics, 2022, 19 : 774 - 784
  • [22] Role of Monoclonal Antibody "Alemtuzumab"in the Treatment of Multiple Sclerosis
    Nosher, Sadia
    Fuad, Sehrish
    Mishra, Nupur
    Alrashid, Zaid A.
    Rathod, Bindu
    Mohan, Devyani
    Basavanagowda, Deepak M.
    Kaur, Arveen
    Heindl, Stacey E.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (02)
  • [23] Monoclonal Antibodies in Pregnancy and Breastfeeding in Patients with Multiple Sclerosis: A Review and an Updated Clinical Guide
    Gklinos, Panagiotis
    Dobson, Ruth
    PHARMACEUTICALS, 2023, 16 (05)
  • [24] Therapeutic Monoclonal Antibodies and Multiple Sclerosis: The Essentials
    Heliopoulos, Ioannis
    Patousi, Athanasia
    MEDICINAL CHEMISTRY, 2018, 14 (02) : 144 - 154
  • [25] Emerging therapies for multiple sclerosis
    de Lorenzo-Pinto, Ana
    Guadalupe Rodriguez-Gonzalez, Carmen
    Ais-Larisgoitia, Arantza
    MEDICINA CLINICA, 2013, 140 (02): : 76 - 82
  • [26] Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review
    Brown, Justin D.
    Muston, Benjamin T.
    Massey, Jennifer
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 86
  • [27] Use of polyclonal/monoclonal antibody therapies in transplantation
    Yeung, Melissa Y.
    Gabardi, Steven
    Sayegh, Mohamed H.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (03) : 339 - 352
  • [28] Anti-CD20 therapies for pediatric-onset multiple sclerosis: A systematic review
    Etemadifar, Masoud
    Nouri, Hosein
    Sedaghat, Nahad
    Ramezani, Aryana
    Kargaran, Parisa K.
    Salari, Mehri
    Kaveyee, Hasan
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [29] Disease-modifying therapies in multiple sclerosis: A focused review of rituximab
    Alping, Peter
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2023, 133 (05) : 550 - 564
  • [30] Treating multiple sclerosis with monoclonal antibodies: a 2010 update
    Buttmann, Mathias
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (05) : 791 - 809
12345